MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease
Jin Wang,Jinyun Chen,Ping Chang,Aimee Leblanc,Donghui Li,James L. Abbruzzesse,Marsha L. Frazier,Ann M. Killary,Subrata Sen +8 more
Reads0
Chats0
TLDR
Observations show the feasibility of developing plasma miRNA profiling as a sensitive and specific blood-based biomarker assay for pancreatic cancer that has the potential of translation to the clinic with additional improvements in the future.Abstract:
Development of minimally invasive biomarker assays for early detection and effective clinical management of pancreatic cancer is urgently needed to reduce high morbidity and mortality associated with this malignancy We hypothesized that if aberrantly expressing microRNAs (miRNA) in pancreatic adenocarcinoma tissues are detected in blood plasma, then plasma profiling of these miRNAs might serve as a minimally invasive early detection biomarker assay for this malignancy By using a modified protocol to isolate and quantify plasma miRNAs from heparin-treated blood, we show that miRNA profiling in plasma can differentiate pancreatic adenocarcinoma patients from healthy controls We have profiled four miRNAs, miR-21, miR-210, miR-155, and miR-196a, all implicated in the development of pancreatic cancer with either proven or predicted target genes involved in critical cancer-associated cellular pathways Of these, miR-155 has recently been identified as a candidate biomarker of early pancreatic neoplasia, whereas elevated expression of miR196a has been shown to parallel progression of disease The results revealed a sensitivity of 64% and a specificity of 89% with the analyses of plasma levels for this panel of four miRNAs The area under the receiver operating characteristic curve were estimated at 082 and 078 without and with leave-one-out cross-validation scheme, respectively These observations, although a "proof of principle" finding at this time, show the feasibility of developing plasma miRNA profiling as a sensitive and specific blood-based biomarker assay for pancreatic cancer that has the potential of translation to the clinic with additional improvements in the futureread more
Citations
More filters
Journal ArticleDOI
MicroRNAs in body fluids—the mix of hormones and biomarkers
Maria Angelica Cortez,Carlos E. Bueso-Ramos,Jana Ferdin,Gabriel Lopez-Berestein,Anil K. Sood,George A. Calin +5 more
TL;DR: The role of fluid-expressedmiRNAs as reliable cancer biomarkers and treatment-response predictors as well as potential new patient selection criteria for clinical trials are discussed and the concept that miRNAs could function as hormones is explored.
Journal ArticleDOI
Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis.
TL;DR: The usefulness of circulating miRNA for cancer diagnosis, prognosis, and therapeutics is summarized and a mechanism for the secretion and incorporation of miRNA into the cells is proposed.
Journal ArticleDOI
MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy
TL;DR: Progress in using mouse models to understand the roles ofmiRNAs in cancer and the potential for manipulating miRNAs for cancer therapy as these molecules make their way towards clinical trials are discussed.
Journal ArticleDOI
Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies.
Colin C. Pritchard,Evan M. Kroh,Brent L. Wood,Jason D. Arroyo,Katy Dougherty,Melanie M. Miyaji,Jonathan F. Tait,Muneesh Tewari +7 more
TL;DR: Evidence is presented that blood cells are a major contributor to circulating miRNA and that perturbations in blood cell counts and hemolysis can alter plasma miRNA biomarker levels by up to 50-fold.
Journal ArticleDOI
miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis
Carmen Elena Condrat,Dana Claudia Thompson,Madalina Gabriela Barbu,Oana Larisa Bugnar,Andreea Elena Boboc,Dragos Cretoiu,Nicolae Suciu,Sanda Maria Cretoiu,Silviu Cristian Voinea +8 more
TL;DR: There is promising evidence that in spite of the lack of standardized protocols regarding the use of miRNA in current clinical practice, they constitute a reliable tool for future use, and it is anticipated that miRNAs will become a routine approach in the development of personalized patient profiles, thus permitting more specific therapeutic interventions.
References
More filters
Journal ArticleDOI
MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer.
Irfan A. Asangani,Suhail Ahmed Kabeer Rasheed,D. A. Nikolova,Jörg H. Leupold,Nancy H. Colburn,Stefan Post,Heike Allgayer +6 more
TL;DR: This is the first study to show that Pdcd4 is negatively regulated by miR-21, and the first report to demonstrate that mi R-21 induces invasion/intravasation/metastasis.
Journal ArticleDOI
Phases of Biomarker Development for Early Detection of Cancer
Margaret S. Pepe,Ruth Etzioni,Ziding Feng,John D. Potter,Mary Lou Thompson,Mark D. Thornquist,Marcy Winget,Yutaka Yasui +7 more
TL;DR: The purpose of this commentary is to define a formal structure to guide the process of biomarker development and to provide a checklist of issues that should be addressed at each phase of development before proceeding to the next.
Journal ArticleDOI
miRNAs, cancer, and stem cell division.
Carlo M. Croce,George A. Calin +1 more
TL;DR: As a cluster of recent Nature papers now show, altered expression of specific miRNA genes contributes to the initiation and progression of cancer.
Journal ArticleDOI
MicroRNAs in cell proliferation, cell death, and tumorigenesis.
Hun-Way Hwang,Joshua T. Mendell +1 more
TL;DR: How miRNAs influence tumorigenesis by acting as oncogenes and tumour suppressors is discussed.
Journal ArticleDOI
MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis.
Mark Bloomston,Wendy L. Frankel,Fabio Petrocca,Stefano Volinia,Stefano Volinia,Hansjuerg Alder,John P. Hagan,Chang Gong Liu,Darshna Bhatt,Cristian Taccioli,Carlo M. Croce +10 more
TL;DR: Pancreatic cancer may have a distinct miRNA expression pattern that may differentiate it from normal pancreas and chronic pancreatitis, but these findings need to be validated in other study populations.
Related Papers (5)
Circulating microRNAs as stable blood-based markers for cancer detection
Patrick S. Mitchell,Rachael K. Parkin,Evan M. Kroh,Brian R. Fritz,Brian R. Fritz,Stacia K. Wyman,Era L. Pogosova-Agadjanyan,Amelia Peterson,Jennifer Noteboom,Kathy O'Briant,April Allen,Daniel W. Lin,Daniel W. Lin,Daniel W. Lin,Nicole Urban,Charles W. Drescher,Beatrice S. Knudsen,Derek L. Stirewalt,Robert Gentleman,Robert L. Vessella,Robert L. Vessella,Peter S. Nelson,Daniel Martin,Daniel Martin,Muneesh Tewari +24 more
Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases
Xi Chen,Yi Ba,Lijia Ma,Lijia Ma,Xing Cai,Yuan Yin,Kehui Wang,Jigang Guo,Yujing Zhang,Jiangning Chen,Xing Guo,Qibin Li,Qibin Li,Xiaoying Li,Wenjing Wang,Yan Zhang,Jin Wang,Xueyuan Jiang,Yang Xiang,Chen Xu,Pingping Zheng,Juanbin Zhang,Ruiqiang Li,Hongjie Zhang,Xiaobin Shang,Ting Gong,Guang Ning,Jun Wang,Jun Wang,Ke Zen,Junfeng Zhang,Chen-Yu Zhang +31 more
MicroRNA expression profiles classify human cancers
Jun Lu,Gad Getz,Eric A. Miska,Eric A. Miska,Ezequiel Alvarez-Saavedra,Justin Lamb,David Peck,Alejandro Sweet-Cordero,Alejandro Sweet-Cordero,Benjamin L. Ebert,Benjamin L. Ebert,Raymond H. Mak,Raymond H. Mak,Adolfo A. Ferrando,James R. Downing,Tyler Jacks,H. Robert Horvitz,H. Robert Horvitz,Todd R. Golub,Todd R. Golub,Todd R. Golub +20 more